Shares of BioAge Labs, Inc. (NASDAQ:BIOA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $29.00.
Several research firms have weighed in on BIOA. Citigroup dropped their target price on BioAge Labs from $21.00 to $20.00 and set a "buy" rating for the company in a research report on Wednesday. Wall Street Zen cut shares of BioAge Labs from a "sell" rating to a "strong sell" rating in a research report on Saturday, October 10th. Weiss Ratings upgraded BioAge Labs from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, October 26th. BTIG Research reiterated a "buy" rating on shares of BioAge Labs in a report on Monday, November 9th. Finally, Jefferies Financial Group set a $21.00 target price on BioAge Labs in a research note on Friday, July 31st.
View Our Latest Analysis on BioAge Labs
BioAge Labs Trading Down 1.3%
Shares of BIOA opened at $4.71 on Friday. The firm has a market cap of $216.47 million, a P/E ratio of -1.85 and a beta of 1.19. BioAge Labs has a 12-month low of $4.45 and a 12-month high of $25.95. The company's 50-day moving average price is $6.26 and its 200 day moving average price is $14.85.
BioAge Labs (NASDAQ:BIOA - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.05). BioAge Labs had a negative return on equity of 31.42% and a negative net margin of 1,253.60%. The company had revenue of $0.30 million for the quarter. Equities research analysts forecast that BioAge Labs will post -2.59 earnings per share for the current year.
Hedge Funds Weigh In On BioAge Labs
Institutional investors and hedge funds have recently made changes to their positions in the stock. a16z Capital Management L.L.C. purchased a new stake in shares of BioAge Labs during the third quarter worth approximately $22,923,000. BlackRock Inc. purchased a new stake in shares of BioAge Labs during the 2nd quarter worth $69,831,000. Jupiter Topco LLC acquired a new position in shares of BioAge Labs during the second quarter worth $52,597,000. Janus Henderson Group PLC grew its stake in shares of BioAge Labs by 411.8% during the first quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company's stock worth $36,597,000 after purchasing an additional 1,685,063 shares in the last quarter. Finally, Octagon Capital Advisors LP increased its holdings in BioAge Labs by 9.4% in the first quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company's stock valued at $30,573,000 after buying an additional 150,000 shares during the last quarter.
About BioAge Labs
(
Get Free Report)
BioAge Labs is a clinical-stage biopharmaceutical company developing medicines for metabolic diseases by targeting biological pathways associated with aging. Its research platform draws on human data to identify age-related mechanisms that may be relevant to disease and treatment. The company's pipeline includes BGE-102, an investigational oral inhibitor of the NLRP3 protein, which is being developed for metabolic conditions. BioAge previously studied azelaprag, an apelin-receptor agonist, but discontinued its development after safety concerns arose in a clinical trial.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioAge Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioAge Labs wasn't on the list.
While BioAge Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.